AtriCure, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $534.5M | $465.3M | $399.2M | $330.4M | $274.3M |
| Cost of revenue | $133.7M | $117.8M | $98.9M | $84.4M | $68.5M |
| Gross profit | $400.8M | $347.5M | $300.4M | $245.9M | $205.9M |
| Selling, general & administrative | $311.0M | $291.4M | $253.1M | $231.3M | $204.6M |
| Research and development | $99.2M | $96.2M | $73.9M | $57.3M | $48.5M |
| Operating expenses | $410.2M | $387.5M | $327.1M | $288.6M | $150.7M |
| Operating income | -$9.4M | -$40.0M | -$26.7M | -$42.7M | $55.2M |
| Interest expense | $5.9M | $6.4M | $6.9M | $5.0M | $4.9M |
| Pretax income | -$10.2M | -$43.7M | -$29.8M | -$46.2M | $50.4M |
| Income tax expense | $1.3M | $1.0M | $591,000 | $268,000 | $188,000 |
| Net income | -$11.4M | -$44.7M | -$30.4M | -$46.5M | $50.2M |
| Balance Sheet | |||||
| Cash and equivalents | $167.4M | $122.7M | $84.3M | $58.1M | $43.7M |
| Current assets | $322.5M | $267.8M | $266.2M | $215.2M | $196.1M |
| Total assets | $654.2M | $609.3M | $613.9M | $585.4M | $615.3M |
| Current liabilities | $81.5M | $73.4M | $74.6M | $58.4M | $56.4M |
| Total liabilities | $162.2M | $148.4M | $147.8M | $128.7M | $131.6M |
| Stockholders' equity | $491.9M | $461.0M | $466.2M | $456.8M | $483.8M |
| Cash Flow Statement | |||||
| Cash from operations | $57.3M | $12.2M | $4.5M | -$22.1M | -$13.8M |
| Depreciation and amortization | $12.1M | $11.2M | $9.5M | $8.1M | $7.5M |
| Stock-based compensation | $44.7M | $40.4M | $35.7M | $28.8M | $28.1M |
| Capital expenditure | $9.1M | $11.5M | $12.0M | $16.9M | $9.8M |
| Free cash flow | $48.3M | $745,000 | -$7.5M | -$39.0M | -$23.5M |
| Impairments | — | — | $0 | $0 | $82.3M |
Shares outstanding 50.6M · Free float 84.4%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.